COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs Albumin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00287664
Recruitment Status : Suspended (because in a preliminary analysis we would need 1000 patients per group to achieve significative differences in the main end point.)
First Posted : February 7, 2006
Last Update Posted : April 11, 2007
Grant from Education Ministery from 2001-2004.
Information provided by:
Hospital Clinic of Barcelona

Brief Summary:
Hepatorenal syndrome is a common complication of cirrhotic patients. The prognosis of patients with HRS is very poor. It have been demonstrated that vasoconstrictors agents (Terlipressin) plus albumin are effective in the reversal of the treatment. However, previous studies are pilot studies and they are not able to give information about an improvement in survival. This comparative randomized study was delineated to test the efficacy of terlipressin on survival.

Condition or disease Intervention/treatment Phase
Cirrhosis Hepatorenal Syndrome Drug: terlipressin Phase 4

Detailed Description:
Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Terlipressin as Treatment of Patients With Cirrhosis and Hepatorenal Syndrome. Effect on Survival and Renal Function. Multicenter, Randomized and Prospective Study
Study Start Date : February 2002
Study Completion Date : September 2006

Primary Outcome Measures :
  1. Survival

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with HRS type 1 or 2 with serum creatinine >2 mg/dL
  2. Age between 18 and 75 years
  3. Written informed consent.
  4. Absence of exclusion criteria

Exclusion Criteria:

  1. Hepatocarcinoma (3 nodules greater than 3 cm or 1 nodule > than 5 cm)
  2. Active infection with systemic inflammatory response syndrome
  3. Respiratory or cardiac dysfunction.
  4. Arteriopathy.
  5. Ischemic cardiopathy.
  6. Arterial hypertension ( >140/90 mmHg during hospitalization )

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00287664

Layout table for location information
Hospital Clinic
Barcelona, Spain, 08036
Sponsors and Collaborators
Hospital Clinic of Barcelona
Grant from Education Ministery from 2001-2004.
Layout table for investigator information
Principal Investigator: Pere Gines, MD Chair of Liver Unit
Layout table for additonal information Identifier: NCT00287664    
Other Study ID Numbers: TAHRS
First Posted: February 7, 2006    Key Record Dates
Last Update Posted: April 11, 2007
Last Verified: April 2007
Keywords provided by Hospital Clinic of Barcelona:
hepatorenal syndrome
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Cirrhosis
Hepatorenal Syndrome
Pathologic Processes
Liver Diseases
Digestive System Diseases
Kidney Diseases
Urologic Diseases
Antihypertensive Agents
Vasoconstrictor Agents